SCHEMBL5867063

SCHEMBL5867063

ON/C(=N\c1ccccc1)c1cc2ccccc2o1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 6/20 0.52
FLT3 P36888 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
TP53 P04637 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
PKM P14618 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
MEN1 O00255 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
GALK1 P51570 1/20 0.43
PIK3CA P42336 2/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5867064 1.00 IDO1 (0.52) IDO1FLT3NPC1RAB9ATP53
SCHEMBL5866931 0.84 IDO1 (0.55) IDO1NPC1RAB9AKMT2AALDH1A1
SCHEMBL5866930 0.84 IDO1 (0.55) IDO1NPC1RAB9AKMT2AALDH1A1
SCHEMBL5866761 0.81 BCAT1 (0.50) IDO1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL5866760 0.81 BCAT1 (0.50) IDO1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL5867015 0.79 ALDH1A1 (0.57) IDO1NPC1RAB9AMEN1KMT2A
SCHEMBL5867012 0.79 ALDH1A1 (0.57) IDO1NPC1RAB9AMEN1KMT2A
SCHEMBL5866921 0.75 IDO1 (0.62) IDO1MEN1TSHRKMT2AALDH1A1
SCHEMBL5866942 0.73 CYP1A2 (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL5866946 0.73 CYP1A2 (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060270651-A1 ANTIBACTERIAL AGENTS AMGEN INC. (US) 2006-11-30 US disclosed
US-7053234-B2 Antibacterial agents AMGEN INC. (US) 2006-05-30 US disclosed
US-20040235911-A1 hydroxyamidines; antibiotic resistance TULARIK INC. 2004-11-25 US disclosed
US-6780858-B2 Antibacterial agents TULARIK INC. 2004-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235911-A1 hydroxyamidines; antibiotic resistance HNMT, HDHD5, ABCC1 IDO1 3464/4885FLT3 3226/4885NPC1 2881/4885
US-20060270651-A1 ANTIBACTERIAL AGENTS MRPL21, HDHD5, CLPP IDO1 3821/4885FLT3 3779/4885NPC1 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.